Boston Scientific announced that the FDA has granted approval to its pulsed field ablation system, FaraPulse, for the treatment of atrial fibrillation. This innovative system utilises non-thermal electric field pulses to gradually remove or ablate heart tissue while preserving the health of surrounding tissues and structures.
In contrast to traditional methods that involve inserting a catheter into the heart and using extreme temperatures to eliminate problematic areas causing abnormalities, FaraPulse sets a high standard for performance. The system has demonstrated its efficacy in both clinical and commercial settings, with over 40,000 patients treated to date.
Nick Spadea-Anello, the President of Electrophysiology at Boston Scientific, expressed confidence in the system's capabilities, stating, "A high bar has been set by the performance of the system in clinical and commercial settings, and we look forward to continuing to lead the way with this differentiated technology in the growing PFA space."
Following the FDA's approval, Boston Scientific is set to promptly launch the FaraPulse system in the United States. This approval marks a significant milestone in providing a more advanced and less damaging treatment option for recurrent, symptomatic, and intermittent atrial fibrillation.
Click here to read the original news story.